Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.
about
Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatmentsManagement of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancerAnalysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsHistopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumorsEGFR-TKI resistance in NSCLC patients: mechanisms and strategiesMeta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs.Dynamic monitoring of EGFR mutations in circulating cell-free DNA for EGFR-mutant metastatic patients with lung cancer: Early detection of drug resistance and prognostic significanceOsimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapyEffect of AXL on the epithelial-to-mesenchymal transition in non-small cell lung cancer.Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidenceEfficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutationsAZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.Lung cancer in the era of precision medicineFrequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patientsAcquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib.Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study.Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.A sensitive and practical method to detect the T790M mutation in the epidermal growth factor receptor.Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patientsRebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure.Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients.The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M.A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistanceTyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer and Eye Metastasis: Disease Relapse or a New Entity?Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: A case report.Readministration of EGFR tyrosine kinase inhibitor in non-small cell lung cancer patients after initial failure, what affects its efficacy?A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer.Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance.A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity.Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC).The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.
P2860
Q26741814-C0BC11FF-7557-415E-879B-984937B7360AQ26852206-FD03C745-A2DF-49E8-8D3E-443E0C618A46Q26865779-13EE6551-27ED-464A-8B22-A43953943E6BQ27852116-B71B1842-4CB1-4AB0-8C95-9691CBBB6D4FQ28075291-AEF6CF81-AADE-4878-95F6-54B0EE16B3DCQ28077504-196398ED-3A97-4D95-9909-5769375328F4Q28394310-DD01B34E-EF3B-48E1-83D3-58051BF1E971Q33621143-A709699F-6164-4269-80F8-5B1930120185Q33751216-58947397-35C7-4856-ACD0-7CCD4A921599Q33757134-10F79EBD-A86D-4B49-9090-DFC499761004Q33847457-B39D680F-F26E-4CFC-A529-B41A3AA34490Q34011705-1A2FA85E-27F5-4E86-97A0-68322042C203Q34055400-D8D0692B-B5D7-4D73-94C2-E24BEF9A73B1Q34497467-7625F3DE-E0C4-4DB3-9AA8-0879EE07A436Q34535332-670EDD09-B210-4354-A6DF-A20BB17B5D33Q35861107-0ECB02E1-A209-46A3-ABEC-A85B207A54EBQ36184824-DFD8EAC1-C5E2-4719-978C-3B1952BA06E0Q36262907-054ABE89-CC4E-45C5-BCA7-DB38D86FE6B2Q36574146-3D7D0759-672A-42BF-A8E7-BF7BA213D883Q36622073-B9CFA8C2-112D-415D-80F0-D37D50D8047DQ36660669-E96654B8-FF4E-48E5-B0E3-139E07E21B07Q36742126-C19DF84B-CBF8-4805-B1FD-15B3C5D41F2FQ37019034-A95C1DC1-14B5-481F-9498-753F253B7F2FQ37022191-A53B7905-B248-4BA5-A4F3-D876D2881D28Q37098321-5371A645-2494-403C-9A0C-2BD17A0062BDQ37393680-2B243D67-6124-456A-AAE3-EE44114E0DBEQ37565381-0B268978-AFA9-4D61-B910-C4751F1D8F43Q37609221-8DF3F767-5885-490F-8DBF-A05D2260F67AQ37694116-14A1DC64-AD3D-493A-A8C7-B1F621F53061Q37731945-C36EB8F8-7C90-4B46-9B11-C84AD8A8248AQ37738403-F7460942-F01E-40D7-8C5E-0079D46C0810Q37742623-45348D03-15AA-42C1-AE68-02290DF8F9E0Q38263354-1D92D2D1-9C2B-4A39-BFE1-985403B0BD2BQ38390205-A75BFBFA-4CF8-43AC-A855-CA580AC8070DQ38504491-01FAC04C-9D59-4D33-B592-E56A7077B377Q38671947-0EC5B045-EAFA-4884-A45A-78F0562CC7EDQ38676692-90AFC181-779B-4A24-B94A-F5F4246540FCQ38940140-DCC28ADA-309C-4327-B2FD-20DED4B45742Q39121571-BCC6B4CA-4DF9-40B3-907F-206B8029D3F2Q39131033-ACAAA923-1C29-4777-91E5-1158F038DF48
P2860
Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Rebiopsy of non-small cell lun ...... mutation-negative populations.
@en
Rebiopsy of non-small cell lun ...... mutation-negative populations.
@nl
type
label
Rebiopsy of non-small cell lun ...... mutation-negative populations.
@en
Rebiopsy of non-small cell lun ...... mutation-negative populations.
@nl
prefLabel
Rebiopsy of non-small cell lun ...... mutation-negative populations.
@en
Rebiopsy of non-small cell lun ...... mutation-negative populations.
@nl
P2093
P2860
P356
P1433
P1476
Rebiopsy of non-small cell lun ...... mutation-negative populations
@en
P2093
Akihiro Nishiyama
Akito Hata
Hiroshige Yoshioka
Jumpei Takeshita
Kazuma Nagata
Kazuya Monden
Kei Kunimasa
Keisuke Tomii
Kosuke Tanaka
Kyoko Otsuka
P2860
P304
P356
10.1002/CNCR.28364
P407
P50
P577
2013-09-16T00:00:00Z